Coos Baakman

Coos Baakman

Auto-generated profile, based on publicly available information

Coos Baakman

Medical BioSciences Department, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
EREve Richardson
Eve Richardson
YAYannick Jurriaan Maria Aarts
Yannick Jurriaan Maria Aarts
JAJohn A Altin
John A Altin
CBCoos A. B. Baakman
Coos A. B. Baakman
PBPhilip Bradley
Philip Bradley
BPBjoern Peters
Bjoern Peters
T cell receptors (TCRs) can bind to peptides presented by MHC molecules (pMHC) as a first step to trigger a T cell response. Reliable approaches to predict TCR:pMHC binding would have broad applications in clinical diagnostics, therapeutics, and the fundamental understanding of molecular interactions. IMMREP is a community organized series of prediction contests that asks participants to predict TCR:pMHC binding on unpublished datasets. Previous iterations in 2022 and 2023 showed multiple approaches can predict TCR-pMHC binding with significant accuracy (median AUC_0.1≥0.7) for peptides where experimental data is available (“seen” peptides). In contrast, models did not outperform random guessing for peptides that have no such data available (“unseen” peptides). Here we report on the results of IMMREP25, which focused solely on unseen peptides in order to evaluate the cutting edge of the field. We received 126 named submissions predicting the specificity of 1,000 TCRs against twenty unseen peptides restricted by one of two MHC molecules (HLA-A*02:01 and HLA-B*40:01). The best performing methods showed a macro-AUC_0.1 of 0.60, significantly better than random, demonstrating significant advances in the field. The top performing methods incorporated structural modeling into their approach, indicating that especially for ‘unseen’ peptides, a structural understanding aids in the prediction of TCR:pMHC interactions. The results from this benchmark highlight the significant challenges remaining for TCR:pMHC predictions and will inform future method development.

27 February 2024 in Journal of Open Source Software
Verified
Journal Article
Open access
PDF file
GCGiulia Crocioni
Giulia Crocioni
DBDani L. Bodor
Dani L. Bodor
CBCoos Baakman
Coos Baakman
FPFarzaneh M. Parizi
Farzaneh M. Parizi
DRDaniel Tobias Rademaker
Daniel Tobias Rademaker
LXLi C. Xue
Li C. Xue
We present DeepRank2, a deep learning (DL) framework geared towards making predictions on 3D protein structures for variety of biologically relevant applications. Our software can be used for predicting structural properties in drug design, immunotherapy, or designing novel proteins, among other fields. DeepRank2 allows for transformation and storage of 3D representations of both protein-protein interfaces (PPIs) and protein single-residue variants (SRVs) into either graphs or volumetric grids containing structural and physico-chemical information. These can be used for training neural networks for a variety of patterns of interest, using either our pre-implemented training pipeline for graph neural networks (GNNs) or convolutional neural networks (CNNs) or external pipelines. The entire framework flowchart is visualized in Figure 1. The package is fully open-source, follows the community-endorsed FAIR principles for research software, provides user-friendly APIs, publicly available documentation, and in-depth tutorials.

22 January 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
CBCoos Baakman
Coos Baakman
GCGiulia Crocioni
Giulia Crocioni
CGCunliang Geng
Cunliang Geng
DRDaniel Tobias Rademaker
Daniel Tobias Rademaker
DFDavid Frühbuß
David Frühbuß
LXLi C. Xue
Li C. Xue
Identifying tumor peptides that bind patient MHC proteins and elicit immune responses is central to immunotherapy, yet progress remains limited to a handful of well-studied alleles. Structure-based methods generalize better than sequence-only models but are constrained by the high computational cost of 3D modeling. We present SwiftMHC, the fastest structure-based framework for peptide–MHC (pMHC) modeling and binding affinity prediction. SwiftMHC predicts peptide–MHC binding in 0.009 sec/case in batch mode on a single A100 GPU—nearly an order of magnitude faster than leading sequence-based methods such as NetMHCpan 4.1 (0.081 sec/case)—while performing competitively in predictive accuracy. In addition to affinity estimation, SwiftMHC generates all-atom 3D pMHC structures and achieves a median Cα-RMSD of 1.32 Å against X-ray benchmarks, matching or better than the accuracy of state-of-the-art approaches (e.g., AlphaFold with fine-tuning) but running thousands of times faster (excluding disk-writing time). These results demonstrate the power of task-specific AI trained on physics-derived synthetic data to overcome the scarcity of experimental structures. Optimized for HLA-A*02:01 9-mers but readily extensible to other alleles, SwiftMHC enables rapid and accurate identification of peptides distinct from self at T-cell–exposed surfaces. This capability may expand immunotherapy targets, improve the safety of TCR-based therapies, and accelerate the development of next-generation cancer immunotherapies.

1 May 2025 in bioRxiv
Verified
Preprint
Open access
DFDavid Frühbuß
David Frühbuß
CBCoos Baakman
Coos Baakman
STSiem Teusink
Siem Teusink
EBErik Bekkers
Erik Bekkers
SJStefanie Jegelka
Stefanie Jegelka
LXLi C. Xue
Li C. Xue
Accurate modeling of peptide–MHC (Major Histocompatibility Complex) structures is critical for the development of personalized cancer vaccines and T-cell therapies, as MHC proteins present peptides on the cell surface for immune recognition. Here, we introduce MHC-Diff, a specialized SE(3)-equivariant diffusion model leveraging Geometric Deep Learning to predict the 3D C-alpha atom structures of peptide–MHC complexes with high accuracy. Unlike previous deep learning models that generate a single static structure, our probabilistic approach samples multiple diverse candidates, capturing the inherent flexibility of peptide–MHC binding. Validated on the Pandora benchmark and experimental X-ray crystallography data, MHC-Diff achieves sub-angstrom accuracy, outperforming existing methods by a large margin while matching the inference speed of the fastest available techniques. By enabling rapid and highly accurate structure prediction across diverse peptide lengths and MHC alleles, MHC-Diff provides a powerful new tool for accelerating the design of next-generation cancer vaccines and T-cell therapies.

31 March 2026 in Cell Reports Methods
Verified
Journal Article
Open access
CBCoos A.B. Baakman
Coos A.B. Baakman
GCGiulia Crocioni
Giulia Crocioni
CGCunliang Geng
Cunliang Geng
DRDaniel T. Rademaker
Daniel T. Rademaker
DFDavid Frühbuß
David Frühbuß
LXLi C. Xue
Li C. Xue
We developed SwiftMHC, an ultra-fast and accurate structure-based framework for peptide-MHC (pMHC) modeling and binding affinity prediction. Using task-specific deep learning trained on physics-derived synthetic data, SwiftMHC predicts pMHC binding affinities in 0.009 s per case on a single A100 GPU when running in batch mode, offering improved speed compared with leading sequence-based tools such as netMHCpan and MHCflurry while maintaining competitive accuracy. In addition, SwiftMHC generates all-atom 3D pMHC structures with a median Cα-RMSD of 1.32 Å against crystallographic benchmarks, matching or exceeding state-of-the-art methods such as AlphaFold2-finetune but at a lower computational cost. Optimized for HLA-A∗02:01 9-mer peptides but readily extensible to other alleles, SwiftMHC unites structural insight with high-throughput scalability to accelerate safe and effective epitope discovery in cancer immunotherapy.